F-18 Fluciclovine Positron Emission Tomography: The New Kid On The Block

David S. Lin
Henry Ford Health System

Ishani Dalal
Henry Ford Health System

Follow this and additional works at: https://scholarlycommons.henryford.com/merf2019edu

Recommended Citation
https://scholarlycommons.henryford.com/merf2019edu/1

This Poster is brought to you for free and open access by the Medical Education Research Forum 2019 at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Teaching and Education by an authorized administrator of Henry Ford Health System Scholarly Commons. For more information, please contact acabrer4@hfhs.org.
F-18 Fluciclovine (Axumin™) Positron Emission Tomography: The New Kid On The Block

David S Lin MD, Ishani Dalal MD
Henry Ford Health System, Detroit, MI
Introduction

- Prostate cancer is the leading non-skin malignancy in the United States and the second most common cause of cancer-related mortality.
- Since the advent of prostate specific antigen (PSA) serum testing, most cases of prostate cancer are detected while still localized to the prostate gland, enabling treatment by surgical prostatectomy and/or radiation therapy.
- Following treatment, patients are monitored with PSA testing and although often curative, approximately 30% of patients experience a recurrence of their cancer, detected as a rising PSA, termed biochemical recurrence.
- Prostate cancer recurrence may be classified as local, locoregional, or systemic.
  - Type of recurrence influences the choice of therapy offered.
- Detection of extraprostatic recurrence by conventional imaging is very low, 11% in one study, and therefore there is a significant need for more sensitive imaging to detect locations of recurrence.
Molecular Imaging Agents

• The first commercially available FDA-approved prostate specific membrane antigen (PSMA) agent is In-111 capromab pendetide (ProstaScint®)

• New prostate cancer positron emission tomography (PET) agents have recently been developed
  – F-18 Fluciclovine (Axumin™)
  – Ga-68 PSMA
  – C-11 Choline
  – C-11 Acetate
  – F-18 Choline
F-18 Fluciclovine

• Trade name Axumin™
• Synthetic amino acid most similar to glutamine, an important substrate for tumor metabolism
• Enters cells via amino acid transporters LAT1 and ASCT2, which are upregulated in cancer cells, most notably prostate cancer
  – LAT1 and ASCT2 transporters associated with aggressive cancers
• Unlike other amino acids used in metabolic imaging, F-18 Fluciclovine is not metabolized or incorporated into proteins
F-18 Fluciclovine

- F-18 Fluciclovine studies are most likely to be positive with PSA levels >1 ng/mL, however can be positive with lower PSA levels.
- 82% positive predictive value for tumor localization when used in combination with MRI.
- Demonstrates utility in further workup in the setting of a negative bone scan.
- Less sensitive for osseous metastases.
- Initial images (<15 minutes) demonstrate most intense activity within the pancreas and the liver.
- Interpretation is based predominantly on qualitative comparison to tissue background.
Case 1: 86-year-old male with history of biochemical recurrence of prostate cancer. PSA 82 ng/mL.

Maximum intensity projection images (left) demonstrate multiple abnormal foci of increased radiotracer uptake throughout the chest, abdomen, and pelvis.

Select axial fused and PET-only images (right) demonstrate multiple foci of increased radiotracer uptake within the left clavicle, left rib, and right acetabulum. There is increased radiotracer uptake corresponding with an enlarged para-aortic lymph node. Findings compatible with metastatic disease.
Case 2: 57-year-old male with history of biochemical recurrence of prostate cancer status post prostatectomy. PSA = 2.7 ng/mL.

Foci of increased radiotracer uptake in the right obturator region corresponding with prominent but nonenlarged external iliac chain lymph nodes. Findings are compatible with metastatic disease.
Pitfalls

- PSA <1 ng/mL
- Osseous metastases can result in photopenic defects
- Benign prostatic hyperplasia and inflammation (i.e. post radiation) can both result in nonmalignant uptake
- Pituitary adenomas, meningiomas, osteoid osteomas, and adrenal adenomas can result in focal uptake
- Bladder uptake
- Teratoma
Case 3: 55-year-old male with history of prostate cancer and known osseous metastatic disease. PSA 1.1 ng/mL.

Bone scan (left) demonstrates increased radiotracer uptake in the right scapula, left medial clavicle, bilateral ribs, T11 vertebral body, and left pelvis.

F18-Fluciclovine PET (right) demonstrates a photopenic defect in the T11 vertebral body corresponding to diffuse sclerosis in the vertebral body and the known osseous metastatic disease.
Conclusion

- F-18 Fluciclovine is a new and effective PET agent that can be used to diagnose local recurrent or distant metastatic disease in patients with a history of prostate cancer.
- Knowledge of pitfalls as well as potential false positive and false negative uptake patterns is crucial for accurate diagnosis in these patients.